Np mrd loader

Record Information
Version2.0
Created at2022-09-11 21:16:20 UTC
Updated at2022-09-11 21:16:20 UTC
NP-MRD IDNP0319963
Secondary Accession NumbersNone
Natural Product Identification
Common Name(1r,3r,6r,13r,18r,19s,21s,23r)-9-methoxy-10-methyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]tricosa-7(12),9-diene-8,11-dione
Description(1R,3R,6R,13R,18R,19S,21S,23R)-9-methoxy-10-methyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]Tricosa-7(12),9-diene-8,11-dione belongs to the class of organic compounds known as isoquinoline quinones. These are isoquinoline derivative with a structure containing a 5,8-dihydroisoquinoline-5,8-dione skeleton. It was first documented in 2002 (PMID: 31593387). Based on a literature review a significant number of articles have been published on (1R,3R,6R,13R,18R,19S,21S,23R)-9-methoxy-10-methyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]Tricosa-7(12),9-diene-8,11-dione (PMID: 27253005) (PMID: 27583328) (PMID: 36127157) (PMID: 36127156) (PMID: 36127155) (PMID: 36127154).
Structure
Thumb
SynonymsNot Available
Chemical FormulaC20H23N3O5
Average Mass385.4200 Da
Monoisotopic Mass385.16377 Da
IUPAC Name(1R,3R,6R,13R,18R,19S,21S,23R)-9-methoxy-10-methyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0^{2,6}.0^{3,21}.0^{7,12}.0^{14,18}.0^{19,23}]tricosa-7(12),9-diene-8,11-dione
Traditional Name(1R,3R,6R,13R,18R,19S,21S,23R)-9-methoxy-10-methyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0^{2,6}.0^{3,21}.0^{7,12}.0^{14,18}.0^{19,23}]tricosa-7(12),9-diene-8,11-dione
CAS Registry NumberNot Available
SMILES
COC1=C(C)C(=O)C2=C([C@@H]3CO[C@@H]4[C@@H]5C[C@H]6[C@@H](N5)[C@H]([C@@H]2N2CCO[C@H]62)N34)C1=O
InChI Identifier
InChI=1S/C20H23N3O5/c1-7-16(24)12-11(17(25)18(7)26-2)10-6-28-20-9-5-8-13(21-9)15(23(10)20)14(12)22-3-4-27-19(8)22/h8-10,13-15,19-21H,3-6H2,1-2H3/t8-,9-,10-,13+,14+,15+,19+,20+/m0/s1
InChI KeySUTMOLYEXFFQAC-OPERTHDMSA-N
Experimental Spectra
Not Available
Predicted Spectra
Spectrum TypeDescriptionDepositor IDDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 25 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 100 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 252 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 1000 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 50 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 200 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 75 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 300 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 101 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 400 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 126 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 151 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 600 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 176 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 700 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 201 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 800 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 226 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 900 MHz, H2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Chemical Shift Submissions
Not Available
Species
Species of OriginNot Available
Chemical Taxonomy
Description Belongs to the class of organic compounds known as isoquinoline quinones. These are isoquinoline derivative with a structure containing a 5,8-dihydroisoquinoline-5,8-dione skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub ClassIsoquinoline quinones
Direct ParentIsoquinoline quinones
Alternative Parents
Substituents
  • Isoquinoline quinone
  • Isoquinolone
  • Diazanaphthalene
  • Naphthyridine
  • Piperazino-3,4-b-piperidine
  • Azepane
  • N-alkylpiperazine
  • 1,4-diazinane
  • Piperazine
  • Piperidine
  • Vinylogous ester
  • Pyrrolidine
  • Oxazolidine
  • Hemiaminal
  • Ketone
  • Secondary amine
  • Azacycle
  • Secondary aliphatic amine
  • Oxacycle
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Carbonyl group
  • Amine
  • Hydrocarbon derivative
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP0.47ChemAxon
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.34 ŲChemAxon
Rotatable Bond Count1ChemAxon
Refractivity97.96 m³·mol⁻¹ChemAxon
Polarizability38.57 ųChemAxon
Number of Rings7ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDNot Available
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound163028206
PDB IDNot Available
ChEBI IDNot Available
Good Scents IDNot Available
References
General References
  1. Authors unspecified: Childhood Vascular Tumors Treatment (PDQ(R)): Patient Version. 2002. [PubMed:27253005 ]
  2. Authors unspecified: Childhood Esophageal Cancer Treatment (PDQ(R)): Health Professional Version. 2002. [PubMed:31593387 ]
  3. Authors unspecified: Financial Toxicity and Cancer Treatment (PDQ(R)): Health Professional Version. 2002. [PubMed:27583328 ]
  4. Gadot R, Najera R, Hirani S, Anand A, Storch E, Goodman WK, Shofty B, Sheth SA: Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022 Sep 20. pii: jnnp-2021-328738. doi: 10.1136/jnnp-2021-328738. [PubMed:36127157 ]
  5. Koggel LM, Lantinga MA, Buchner FL, Drenth JPH, Frankema JS, Heeregrave EJ, Heringa M, Numans ME, Siersema PD: Predictors for inappropriate proton pump inhibitor use: observational study in primary care. Br J Gen Pract. 2022 Jun 24. pii: BJGP.2022.0178. doi: 10.3399/BJGP.2022.0178. [PubMed:36127156 ]
  6. Lynch C, Harrison S, Emery JD, Clelland C, Dorman L, Collins C, Johansen ML, Lawrenson R, Surgey A, Weller D, Jarbol DE, Balasubramaniam K, Nicholson BD: Variation in suspected cancer referral pathways in primary care: comparative analysis across the International Benchmarking Cancer Partnership. Br J Gen Pract. 2022 Jun 22. pii: BJGP.2022.0110. doi: 10.3399/BJGP.2022.0110. [PubMed:36127155 ]
  7. Barends H, Botman F, Walstock E, Dessel NC, van der Wouden JC, Olde Hartman T, Dekker J, van der Horst HE: Lost in fragmentation - care coordination when somatic symptoms persist: a qualitative study of patients' experiences. Br J Gen Pract. 2022 Oct 27;72(724):e790-e798. doi: 10.3399/BJGP.2021.0566. Print 2022 Nov. [PubMed:36127154 ]
  8. Donaghy E, Huang H, Henderson D, Wang HH, Guthrie B, Thompson A, Mercer SW: Primary care transformation in Scotland: qualitative evaluation of the views of national senior stakeholders and cluster quality leads. Br J Gen Pract. 2022 Jul 20. pii: BJGP.2022.0186. doi: 10.3399/BJGP.2022.0186. [PubMed:36127153 ]
  9. Rondas GA, Macri EM, Oei EH, Bierma-Zeinstra SM, Rijkels-Otters HB, Runhaar J: Association between hip pain and radiographic hip osteoarthritis in primary care: the CHECK cohort. Br J Gen Pract. 2022 Jul 26. pii: BJGP.2021.0547. doi: 10.3399/BJGP.2021.0547. [PubMed:36127152 ]
  10. Oetker-Black SL, Stickley G, Fox JL: Psychometric Evaluation of the Addiction Self-Efficacy Scale. J Nurs Meas. 2022 Sep 1;30(3):508-517. doi: 10.1891/JNM-D-21-00004. [PubMed:36127151 ]
  11. LOTUS database [Link]